Also known as glutamate pyruvate transaminase, ALT, and GPT.
Post hoc ESSENCE subgroup (n=106) showed improvements in ALT, AST, FAST, ELF and PRO‑C3 at week 72 versus placebo; findings presented at AASLD 2026.
Phase III data show targeted visceral and liver fat reductions with minimal lean mass loss and sustained weight loss in obesity and MASLD populations.
Semaglutide 2.4 mg improves liver health in MASH patients, showing benefits across weight loss levels and diverse demographics, according to ESSENCE trial data.
